Comerica Bank Lowers Stock Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Comerica Bank cut its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 136,914 shares of the medical instruments supplier's stock after selling 16,707 shares during the period. Comerica Bank owned approximately 0.61% of LeMaitre Vascular worth $12,615,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. Raymond James Financial Inc. purchased a new stake in LeMaitre Vascular in the 4th quarter worth about $14,900,000. Rockefeller Capital Management L.P. bought a new position in LeMaitre Vascular during the fourth quarter valued at approximately $7,787,000. Segall Bryant & Hamill LLC purchased a new position in shares of LeMaitre Vascular in the fourth quarter worth about $5,446,000. Invesco Ltd. boosted its holdings in shares of LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in LeMaitre Vascular by 45.9% in the fourth quarter. JPMorgan Chase & Co. now owns 147,489 shares of the medical instruments supplier's stock worth $13,590,000 after buying an additional 46,430 shares in the last quarter. Institutional investors own 84.64% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital boosted their price target on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Wells Fargo & Company assumed coverage on LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 target price for the company. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $98.14.

Insider Buying and Selling at LeMaitre Vascular

In related news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. This trade represents a 26.53 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 10.79% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded down $0.46 during trading on Wednesday, reaching $81.63. The stock had a trading volume of 208,612 shares, compared to its average volume of 162,537. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $109.58. The stock has a market cap of $1.84 billion, a PE ratio of 44.61, a P/E/G ratio of 2.22 and a beta of 0.86. The firm's 50 day moving average price is $84.77 and its two-hundred day moving average price is $93.23.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. LeMaitre Vascular's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.44 earnings per share. On average, research analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.98%. LeMaitre Vascular's payout ratio is presently 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.